David Ternant

Summary

Country: France

Publications

  1. pmc Influence of methotrexate on infliximab pharmacokinetics and pharmacodynamics in ankylosing spondylitis
    David Ternant
    Universite Francois Rabelais de Tours, Tours, France
    Br J Clin Pharmacol 73:55-65. 2012
  2. pmc Model-based design of rituximab dosage optimization in follicular non-Hodgkin's lymphoma
    David Ternant
    Universite Francois Rabelais de Tours, Laboratoire de Pharmacologie Toxicologie, CHRU Tours, 2 boulevard Tonnelle, Tours Cedex, France
    Br J Clin Pharmacol 73:597-605. 2012
  3. doi request reprint An enzyme-linked immunosorbent assay to study bevacizumab pharmacokinetics
    David Ternant
    Université François Rabelais de Tours, Genetics, Immunotherapy, Chemistry and Cancer, Tours, France
    Ther Drug Monit 32:647-52. 2010
  4. doi request reprint An enzyme-linked immunosorbent assay for therapeutic drug monitoring of cetuximab
    Nicolas Ceze
    GICC, Université François Rabelais Tours, Tours, France
    Ther Drug Monit 31:597-601. 2009
  5. pmc Infliximab in ankylosing spondylitis: alone or in combination with methotrexate? A pharmacokinetic comparative study
    Denis Mulleman
    Universite Francois Rabelais de Tours, Centre National de la Recherche Scientifique UMR 6239 GICC, 3 rue des Tanneurs, F 37041 Tours Cedex 1, France
    Arthritis Res Ther 13:R82. 2011
  6. pmc Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases
    Emilie Ducourau
    Universite Francois Rabelais de Tours, Centre National de la Recherche Scientifique UMR 6239 GICC, 3 rue des Tanneurs, F 37041 Tours Cedex 1, France
    Arthritis Res Ther 13:R105. 2011
  7. pmc Development of a drug-disease simulation model for rituximab in follicular non-Hodgkin's lymphoma
    David Ternant
    Université François Rabelais Tours, GICC, Tours, France
    Br J Clin Pharmacol 68:561-73. 2009
  8. doi request reprint Trough infliximab concentrations predict efficacy and sustained control of disease activity in rheumatoid arthritis
    Denis Mulleman
    Universite Francois Rabelais de Tours, CNRS, UMR 6239, Tours, France
    Ther Drug Monit 32:232-6. 2010
  9. doi request reprint Tumor burden influences exposure and response to rituximab: pharmacokinetic-pharmacodynamic modeling using a syngeneic bioluminescent murine model expressing human CD20
    David Daydé
    Genetique, Immunothérapie, Chimie et Cancer, Universite Francois Rabelais, Tours, France
    Blood 113:3765-72. 2009
  10. doi request reprint Cetuximab pharmacokinetics influences progression-free survival of metastatic colorectal cancer patients
    Nicolas Azzopardi
    Université François Rabelais Tours, Tours, France
    Clin Cancer Res 17:6329-37. 2011

Collaborators

Detail Information

Publications16

  1. pmc Influence of methotrexate on infliximab pharmacokinetics and pharmacodynamics in ankylosing spondylitis
    David Ternant
    Universite Francois Rabelais de Tours, Tours, France
    Br J Clin Pharmacol 73:55-65. 2012
    ..The objective was to assess the influence of methotrexate on the variability of infliximab pharmacokinetics and concentration-effect relationship in axial ankylosing spondylitis (AAS) patients...
  2. pmc Model-based design of rituximab dosage optimization in follicular non-Hodgkin's lymphoma
    David Ternant
    Universite Francois Rabelais de Tours, Laboratoire de Pharmacologie Toxicologie, CHRU Tours, 2 boulevard Tonnelle, Tours Cedex, France
    Br J Clin Pharmacol 73:597-605. 2012
    ..Previous studies suggest that increasing the dose of rituximab and/or the number of infusions may lead to a better clinical response in FL...
  3. doi request reprint An enzyme-linked immunosorbent assay to study bevacizumab pharmacokinetics
    David Ternant
    Université François Rabelais de Tours, Genetics, Immunotherapy, Chemistry and Cancer, Tours, France
    Ther Drug Monit 32:647-52. 2010
    ..It displays an important interindividual pharmacokinetic variability, which could explain part of the interindividual differences in clinical response. Therefore, an assay to measure bevacizumab serum concentrations is needed...
  4. doi request reprint An enzyme-linked immunosorbent assay for therapeutic drug monitoring of cetuximab
    Nicolas Ceze
    GICC, Université François Rabelais Tours, Tours, France
    Ther Drug Monit 31:597-601. 2009
    ..8-105.4) and 177.2 (97.5-235) mg/L, respectively. This method is rapid, accurate, and reproducible and may be useful for pharmacokinetic and pharmacokinetic-pharmacodynamic studies, as well as in therapeutic drug monitoring of cetuximab...
  5. pmc Infliximab in ankylosing spondylitis: alone or in combination with methotrexate? A pharmacokinetic comparative study
    Denis Mulleman
    Universite Francois Rabelais de Tours, Centre National de la Recherche Scientifique UMR 6239 GICC, 3 rue des Tanneurs, F 37041 Tours Cedex 1, France
    Arthritis Res Ther 13:R82. 2011
    ..However, its combination with infliximab in the treatment of ankylosing spondylitis (AS) is not recommended. The objective of this study was to examine the influence of MTX on infliximab exposure in patients with AS...
  6. pmc Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases
    Emilie Ducourau
    Universite Francois Rabelais de Tours, Centre National de la Recherche Scientifique UMR 6239 GICC, 3 rue des Tanneurs, F 37041 Tours Cedex 1, France
    Arthritis Res Ther 13:R105. 2011
    ..We studied the association of infliximab concentration at treatment initiation and development of ATI as well as the association of the presence of ATI and maintenance of infliximab...
  7. pmc Development of a drug-disease simulation model for rituximab in follicular non-Hodgkin's lymphoma
    David Ternant
    Université François Rabelais Tours, GICC, Tours, France
    Br J Clin Pharmacol 68:561-73. 2009
    ..The aim of this study was to develop a PK-PD model of rituximab in relapsed/resistant follicular NHL (FL)...
  8. doi request reprint Trough infliximab concentrations predict efficacy and sustained control of disease activity in rheumatoid arthritis
    Denis Mulleman
    Universite Francois Rabelais de Tours, CNRS, UMR 6239, Tours, France
    Ther Drug Monit 32:232-6. 2010
    ..01). In rheumatoid arthritis, infliximab concentration is predictive of sustained efficacy with the same infliximab regimen and should be considered on a routine basis...
  9. doi request reprint Tumor burden influences exposure and response to rituximab: pharmacokinetic-pharmacodynamic modeling using a syngeneic bioluminescent murine model expressing human CD20
    David Daydé
    Genetique, Immunothérapie, Chimie et Cancer, Universite Francois Rabelais, Tours, France
    Blood 113:3765-72. 2009
    ..Furthermore, rituximab exposure influenced response and survival. Finally, using a pharmacokinetic-pharmacodynamic model, we demonstrated that tumor burden significantly influenced rituximab efficacy...
  10. doi request reprint Cetuximab pharmacokinetics influences progression-free survival of metastatic colorectal cancer patients
    Nicolas Azzopardi
    Université François Rabelais Tours, Tours, France
    Clin Cancer Res 17:6329-37. 2011
    ....
  11. doi request reprint Infliximab pharmacokinetics in inflammatory bowel disease patients
    David Ternant
    Université François Rabelais Tours, GICC, Tours, France
    Ther Drug Monit 30:523-9. 2008
    ..Both body weight and sex were found to influence infliximab pharmacokinetics, and its clearance increased thrice in the presence of ATI...
  12. doi request reprint Fc gamma RIIIa expression is not increased on natural killer cells expressing the Fc gamma RIIIa-158V allotype
    Nicolas Congy-Jolivet
    EA3853 Immuno Pharmaco Genetique des Anticorps thérapeutiques, Universite Francois Rabelais de Tours, Tours, France
    Cancer Res 68:976-80. 2008
    ..We conclude that increased binding and functional and clinical responses associated with the high-affinity Fc gamma RIIIa-158V are unrelated to an increased expression of this allotype...
  13. ncbi request reprint An enzyme-linked immunosorbent assay for therapeutic drug monitoring of infliximab
    David Ternant
    Universite Francois Rabelais, Immuno Pharmaco Genetics of Therapeutic Antibodies, Tours, France
    Ther Drug Monit 28:169-74. 2006
    ..Data were described using a 1-compartment population pharmacokinetic model. Terminal elimination half-life was 10.9 days. This method is rapid, accurate, and reproducible, and may be useful in therapeutic drug monitoring of infliximab...
  14. doi request reprint [Monoclonals antibodies: a recent and major therapeutic advance]
    Gilles Paintaud
    Universite Francois Rabelais de Tours, GICC, Tours, France
    Therapie 64:1-7. 2009
    ..At present, about twenty monoclonal antibodies are on the market, and a large number is under development...
  15. doi request reprint Pharmacokinetic and pharmacodynamic studies of two different rabbit antithymocyte globulin dosing regimens: results of a randomized trial
    Matthias Buchler
    Universite Francois Rabelais, Tours, France CHRU Tours, Département de Néphrologie et Immunologie Clinique, Tours, France
    Transpl Immunol 28:120-6. 2013
    ..009; Group 2: 32±14% at baseline, 65±14% at one year, p=0.001). In conclusion, our results suggest that the dosing regimen for rATG induction influences pharmacokinetic parameters without affecting the quality of immune reconstitution...
  16. pmc Interindividual variability in the concentration-effect relationship of antilymphocyte globulins - a possible influence of FcgammaRIIIa genetic polymorphism
    David Ternant
    Universite Francois Rabelais, Tours, UPRES EA 3853 Immuno Pharmaco Genetics of therapeutic Antibodies, Tours, France
    Br J Clin Pharmacol 65:60-8. 2008
    ..Moreover, the genetic polymorphism of FcgammaRIIIa, a receptor for the Fc portion of immunoglobulins involved in antibody-dependent cellular cytotoxicity (ADCC), may influence their concentration-effect relationship...